Pleasanton, Calif. and Miami — October 16, 2025 — Leads & Copy — Veeva Systems (NYSE: VEEV) and OpenEvidence have formed a long-term partnership to create and market Open Vista. The AI-powered platform aims to enhance patient access to clinical trials, accelerate drug discovery by improving the understanding of unmet needs, and increase the understanding and adoption of approved medicines to improve patient outcomes.
OpenEvidence CEO Daniel Nadler noted that his company’s clinical decision support AI is actively used by over 40% of U.S. physicians. He added that the partnership with Veeva provides the opportunity to leverage AI to connect physicians and patients with relevant clinical trials and therapies.
Veeva CEO Peter Gassner said the partnership will use AI to bridge life sciences companies making medicines, patients, and their physicians. The first Open Vista product offerings are expected in 2026.
About Veeva Systems
Veeva provides cloud solutions for the life sciences industry, including software, data, and consulting services. It serves over 1,500 customers, ranging from biopharmaceutical companies to emerging biotechs. Veeva is a Public Benefit Corporation committed to balancing the interests of stakeholders.
About OpenEvidence
OpenEvidence is a clinical decision support platform and medical search engine, used by healthcare professionals to make clinical decisions. It is used by over 10,000 hospitals and medical centers and by over 40% of physicians in the United States.
Contacts:
Veeva Systems
PR@veeva.com
OpenEvidence
contact@openevidence.com
Daniel Nadler, CEO of OpenEvidence
Peter Gassner, CEO of Veeva
Source: Veeva Systems
